Affimed Therapeutics Reports Positive Phase 1 Data for Hodgkin's Treatment
Affimed Therapeutics is a research partner of the Leukemia & Lymphoma Society. The major blood cancer charity co-funds the AFM13 research program as part of its Therapy Acceleration Program.
At the most recent annual meeting of the America Association for Cancer Research, Affimed presented data from a Phase 1 trial of a novel immunotherapy treatment, currently known as AFM13.
AFM13 is designed for patients with Hodgkin's lymphoma (HL) for whom currently available treatments have failed. AFM13 is a so-called bispecific antibody that directs natural killer cells to kill CD30-positive cancers like Hodgkin's.
The Phase 1 trial showed that AFM13 met its primary endpoint and demonstrated that AFM13 can be administered safely. It also showed favorable activity in terms of tumor response.
A Phase 2 study investigating optimized dosing will be initiated later this year.
The cure rate for Hodgkin's lymphoma is very high, but for about ten percent of patients, no conventional therapies work, leaving an unmet need in
Source: LLS
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
